Esperion Launched Awareness Campaign for Nasal Diuretic
The campaign prepares medical providers for upcoming CMS payment adjustments regarding heart failure care.
Updated on Oct. 8, 2026 in Heart Disease
Live Poll
Should government payment models prioritize cost-saving measures when determining specialist reimbursement?
Esperion has launched an awareness campaign for its FDA-approved bumetanide nasal spray, a diuretic treatment for edema. The initiative aims to educate healthcare professionals and patients ahead of the January 2027 start of the CMS Ambulatory Specialty Model.
Why it matters
The program helps integrated delivery networks manage heart failure care more efficiently as cardiologists prepare for new Medicare Part B payment adjustments. This alternative to oral medication may reduce the need for more costly intravenous therapy.
A bioequivalence study of 68 healthy adults found the nasal spray reaches peak concentration in 1 hour compared to 1.5 hours for oral tablets. Clinical participants reported adverse reactions, including a 4.8% incidence of hypovolemia and 3% for headache.
The players
Esperion
This pharmaceutical company specializes in developing therapies for patients with cardiovascular disease.
CMS
The Centers for Medicare and Medicaid Services is a federal agency that administers health coverage programs and develops payment models for medical services.
Corstasis Therapeutics
This biotechnology firm was acquired by Esperion to expand its pipeline of specialized cardiovascular treatments.
The details
The spray, approved by the FDA in September 2025, is indicated for edema linked to heart failure, hepatic, and renal diseases at a recommended daily dosage of 0.5 mg to 2 mg. Esperion acquired the treatment through its purchase of Corstasis Therapeutics in April 2026.
Timeline
September 2025: The FDA approved the bumetanide nasal spray.
April 2026: Esperion acquired Corstasis Therapeutics.
September 30, 2026: Esperion announced the awareness campaign.
January 2027: The CMS Ambulatory Specialty Model begins.
Health Landscape
This educational initiative reflects a growing shift toward value-based care models, specifically the CMS Ambulatory Specialty Model, which seeks to standardize outcomes for patients with heart failure. The campaign positions this nasal diuretic as a tool for cardiologists to manage potential payment adjustments.
Patients may find the nasal spray provides a faster-acting alternative to oral diuretics, potentially reducing the need for clinical escalations. Caregivers should monitor for documented side effects like hypovolemia and headache as part of the new treatment routine.
The takeaway
This campaign underscores how medical companies are increasingly aligning product education with federal value-based payment requirements. Patients and providers should discuss how this rapid-absorption diuretic compares to existing standard-of-care tablets for daily edema management.
What happens next
The CMS Ambulatory Specialty Model is scheduled to begin in January 2027, which will trigger Medicare Part B payment adjustments for eligible cardiologists ranging from a 9% reduction to a 9% increase.
Further reading
Learn more about advancements in Heart Disease management and treatment protocols.
More information
Read the full details in the Esperion official news release.
Source note: This article includes information reported by Ajmc.
Live Poll
Should government payment models prioritize cost-saving measures when determining specialist reimbursement?
